Product Name: KinSub4DDDYV
Product Number: PE-01AKS95
Size: 200 µg      Price:99.00
      $US
Peptide Name: KinSub4DDDYV

Product Use: For assaying the phosphotransferase activity of Spleen protein-tyrosine kinase (Syk, UniProt ID P43405). The KinSub4DDDYV peptide demonstrated high phosphotransferase activity with Brk, and exhibited high specificity when assayed with over 200 other protein kinases. A listing of other kinases that show appreciable phosphotransferase activity towards this peptide are listed in Table 1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: KinSub4DDDYV was originally identified using a microarray with peptides that were predicted as optimal substrates for 500 human protein kinases with a proprietary algorithm developed at Kinexus with our academic partners.

Peptide Sequence: FGGEDDDYVGVCGGY

Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1551.6 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: Brk

Scientific Background: Syk is one of several protein kinases that can phosphorylate KinSub4DDDYV. Human Syk is a protein-tyrosine kinase of 635 amino acid length, with a predicted molecular mass of 72,066 Da. It is a member of the TK group of protein kinases in the Syk family. It is moderate to highly expressed in most tested human tissues, particularly in hematopoietic cells. Orthologues are highly conserved in vertebrates, including amphibians. It mediates cell proliferation, differentiation, and phagocytosis. In B cells, Syk plays a crucial role in intracellular signalling induced by oxidative stress as well as antigen receptor engagement (1). Syk is activated by phosphorylation at Y525 and Y526. Phosphorylation of Y348 and Y352 enhances the binding, phosphorylation and activation of PLC-gamma and the early phase of Ca(2+) mobilization via a PI 3-kinase-independent pathway. Phosphorylation of Y131 of Syk inhibits interaction with Bcr. Phosphorylation of Y323 of Syk inhibits B cell Ag receptor signalling and strongly dampens the Ca(2+) signal. Syk is a potential tumour suppressor in breast cancer, where it absence in primary breast tumours is correlated with poor outcomes. Syk deficient cells have increased motility that is restored to normalcy by replacement with wild-type Syk (2). Syk has been linked with the development of allergy, asthma, inflammation, gastric cancer and acute lymphoblastic leukemia.